CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00 vs Viz AAA

Viz AAA offers broader usability due to its cloud-based architecture, mobile access, and seamless integration with existing hospital systems like EHR and PACS, facilitating multidisciplinary care coordination. While CARTO 3 streamlines complex EP procedures for specialists, Viz AAA's focus on system-wide integration and mobile accessibility makes it more broadly usable for diverse care teams. Viz.ai's integration capabilities significantly reduce the time and resources needed by healthcare IT.

Both tools offer significant clinical value. However, Viz AAA is the first FDA-cleared AI solution for the detection and triage of suspected Abdominal Aortic Aneurysm (AAA), a life-threatening condition often missed. Its ability to accelerate diagnosis and intervention for a critical, time-sensitive condition provides a potentially broader and more immediate life-saving impact across a larger patient population. Studies show Viz AAA successfully detected positive aneurysm cases with high sensitivity and specificity.

Viz AAA operates on a subscription model with annual fees based on usage, offering more predictable operational costs and scalability. This model, combined with its demonstrated ability to improve patient outcomes and potentially increase hospital revenue by accelerating treatment, suggests a more flexible and value-driven approach. CARTO 3's pricing is not publicly available and likely involves a significant capital expenditure.

Viz AAA demonstrates superior enterprise readiness with its fully cloud-based deployment, extensive integration capabilities with EHR and PACS, and proven adoption across nearly 2,000 hospitals. It also provides a HIPAA-compliant communication platform for multidisciplinary teams. CARTO 3's core on-premise system, while robust for its specific use, may present more IT overhead for system-wide adoption.

Viz AAA is more innovative by being the *first* FDA-cleared AI-powered solution for the detection and triage of suspected AAA, establishing a new category for AI in diagnostics and care coordination for a critical condition. While CARTO 3 innovates by enhancing complex electrophysiology procedures with AI and deep learning, Viz AAA's pioneering role in a new diagnostic pathway has a broader transformative potential.

Viz AAA offers explicit and comprehensive support, including a dedicated customer success team with Clinical and Workflow Specialists, Customer Success Managers, and Clinical Research Scientists. They also provide 24/7 urgent support via phone and in-app contact, along with a Help Center and customer resources. While Biosense Webster (CARTO 3) is a large company expected to have good support, Viz.ai's offerings are more clearly detailed and proactive.